T-Guard as Treatment for Steroid Refractory Acute GVHD
Status:
Terminated
Trial end date:
2020-02-17
Target enrollment:
Participant gender:
Summary
The study is designed as an open-label, single arm Phase III, multicenter trial to evaluate
the efficacy and safety of T-Guard treatment in patients with Steroid-Refractory acute Graft
versus Host Disease (SR-aGVHD).
Phase:
Phase 3
Details
Lead Sponsor:
Xenikos
Collaborators:
Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI) National Marrow Donor Program